Sonoma Pharmaceuticals, Inc.
SNOA
$3.24
-$0.03-0.92%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 56.58% | 18.40% | 9.16% | 13.58% | 31.05% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 56.58% | 18.40% | 9.16% | 13.58% | 31.05% |
| Cost of Revenue | 57.08% | 22.35% | -5.20% | 36.71% | 27.40% |
| Gross Profit | 55.77% | 12.10% | 40.05% | -13.01% | 37.47% |
| SG&A Expenses | 10.38% | -2.19% | -15.21% | 10.04% | 2.59% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 34.14% | 11.96% | -9.03% | 15.39% | 12.44% |
| Operating Income | 60.35% | 6.65% | 53.44% | -22.16% | 29.64% |
| Income Before Tax | -57.88% | -24.57% | 61.15% | 0.43% | 64.33% |
| Income Tax Expenses | -234.01% | -100.68% | 184.93% | 115.79% | -20.97% |
| Earnings from Continuing Operations | 12.46% | -8.57% | 27.27% | -7.16% | 58.89% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 12.46% | -8.57% | 27.27% | -7.16% | 58.89% |
| EBIT | 60.35% | 6.65% | 53.44% | -22.16% | 29.64% |
| EBITDA | 63.07% | 6.61% | 54.31% | -24.91% | 29.92% |
| EPS Basic | 45.01% | 43.70% | 65.42% | 60.03% | 89.74% |
| Normalized Basic EPS | 0.82% | 35.40% | 81.52% | 62.87% | 91.10% |
| EPS Diluted | 45.01% | 43.70% | 65.42% | 60.03% | 89.74% |
| Normalized Diluted EPS | 0.82% | 35.40% | 81.52% | 62.87% | 91.10% |
| Average Basic Shares Outstanding | 59.19% | 92.83% | 110.30% | 168.13% | 300.78% |
| Average Diluted Shares Outstanding | 59.19% | 92.83% | 110.30% | 168.13% | 300.78% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |